| Subcribe via RSS



Acucela and Otsuka Pharmaceutical Receive FDA Fast Track Designation…

March 17th, 2010

Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50 BOTHELL, Wash.

Original post by BusinessWire


(click on the author/publication link above to see full post)
This entry was posted on Wednesday, March 17th, 2010 at 10:12 pm. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.

«
»